Review Article
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
Table 3
Efficacy of Trastuzumab when given in combination with chemotherapy in
metastatic breast cancer from Slamon et al. [
28].
| | Tratuzumab + AC
(n = 143) | AC alone
(n = 138) | Trastuzumab +
paclitaxel (n = 92) | Paclitaxel alone (n = 96) | Trastuzumab + chemotherapy
(n = 235) | Chemotherapy alone
(n = 234) |
| | Median TTP (months) | 7.8 | 6.1 | 6.9 | 3 | 7.4 | 4.6 | | (P = .0004) | (P = .0001) | (P = .0001) | | Response rate (%) | 56 | 42 | 41 | 17 | 50 | 32 | | (P = .0197) | (P = .0002) | (P < .0001) | | Median duration of response (months) | 9.1 | 6.7 | 10.5 | 4.5 | 9.1 | 6.1 | | (P = .0047) | (P = .00124) | (P = .0002) | | Median TTF (months) | 7.2 | 5.6 | 5.8 | 2.9 | 6.9 | 4.5 | | (P = .0014) | (P = .0001) | (P = .0001) | | 1-year survival (%) | 83 | 72 | 72 | 60 | 79 | 68 | | (P = .0415) | (P = .0975) | (P = .008) | | Median survival (months) | 26.8 | 22.8 | 22.8 | 18.4 | 25.4 | 20.3 | | | | | | (P = .025) |
|
|
AC: Anthracycline; TTP: Time to disease
progression; TTF: Time-to-treatment failure.
|
